Putnam Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Putnam Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-49,331	Closed	-$1.64M	–	957
2018 Q4	$1.64M	Sell	49,331 -7,735	-14%	-$333K	﹤0.01%	672
2018 Q3	$2.87M	Buy	57,066 +39,192	+219%	+$1.94M	0.01%	703
2018 Q2	$1.07M	Buy	+17,874	New	+$926K	﹤0.01%	841
2016 Q4	–	Sell	-78,538	Closed	-$1.94M	–	1285
2016 Q3	$1.94M	Sell	78,538 -114,866	-59%	-$2.6M	﹤0.01%	851
2016 Q2	$3.94M	Buy	193,404 +77,598	+67%	+$1.38M	0.01%	735
2016 Q1	$1.77M	Buy	115,806 +38,284	+49%	+$500K	﹤0.01%	983
2015 Q4	$1.04M	Sell	77,522 -1,325	-2%	-$20.5K	﹤0.01%	1145
2015 Q3	$1.11M	Buy	+78,847	New	+$1.47M	﹤0.01%	1149

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Putnam Investments's SUPN Position: Q1 2019 in Review

Putnam Investments sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 49,331 shares — an estimated $1.64M sold.

Putnam Investments first reported a position in SUPN in Q3 2015 and held it in 8 quarters. The position peaked at $3.94M in Q2 2016. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

Putnam Investments reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Putnam Investments sold 49,331 Supernus Pharmaceuticals shares in Q1 2019, an estimated $1.64M.
Putnam Investments first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 8 quarters.
Putnam Investments's Supernus Pharmaceuticals position peaked at $3.94M in Q2 2016.
289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Putnam Investments's 13F filing for Q1 2019, filed 15 May 2019.